Joseph R. Shaw

For clinicians around the world, the Wells score is a familiar and essential tool used to estimate a patient’s probability of having a blood clot. Now honored with the 2026 ISTH Esteemed Career Award, Dr. Wells reflects on the journey. 🎥 Watch the video and read more: bit.ly/40Pp6GA

🎉 Celebrating the end of a remarkable year with our @uOttawaMed Adult Thrombosis Medicine International Fellows! We're incredibly proud of all you've achieved and the impact you've made. Thank you for your dedication and excellence. 🌍🩸 🇨🇦🇺🇾🇨🇭🇫🇷🇧🇪🇸🇦🇮🇹🇺🇦

How do you manage oral anticoagulants in patients undergoing an invasive dental procedure? Our prospective national study suggests a short DOAC discontinuation before the invasive dental procedure can minimize bleeding! @RPTHjournal doi.org/10.1016/j.rpth…

Have you ever wondered about the long-term risk of recurrence in patients with isolated SSPE? New data suggest the risk may not exceed the threshold for extended duration anticoagulation. Case by case decision is needed. 👉sciencedirect.com/science/articl… @ThrombosisCan @canvector @JRand083 @ThrombosisRese1 @OttMethodsCentr #VTE #PulmonaryEmbolism #MedTwitter

🚨 Distal Deep Vein Thrombosis in pts admitted to Internal Medicine wards: the AURELIO study ⬇️ 📌 1,458 pts included; asymptomatic distal DVT found in 4% 📌 53% of distal #DVT extended to proximal tract 📌 Active #cancer and pneumonia 🔗 with DDVT 👉 thieme-connect.de/products/ejour…

Emergent cardiac surgery after andexanet-reversal can lead to life-threatening heparin resistance and potential thrombotic complications. ⚠️ Maybe we should avoid FXaI reversal with andexanet in patients who might need urgent cardiac surgery! 👉 Read more doi.org/10.1016/j.jtha…

Interesting comments from @GBarnesMD about the #APICAT study #VTE #cancer @ACC25 @APHP @INNOVTE1

Kudos @KeyvanKarkouti et al for this important study

Prof. @isabellemahe1 presents API-CAT at #ACC2025, published in @NEJM Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose for preventing recurrent VTE, with less clinically relevant bleeding 🩸in patients with cancer. nejm.org/doi/full/10.10…

📣🚨I am incredibly happy and proud to share the Prognosis After Transient Ischemic Attack or Minor Stroke (PERSIST) study from my #BantingCanada🇨🇦 postdoctoral fellowship published today in @JAMA_current! jamanetwork.com/journals/jama/…

Post-hoc analysis of the Hokusai VTE Cancer trial showed that treatment for recurrent VTE on AC were heterogeneous, and there were high risks of second recurrent VTE (9%) and major bleeding (10%) within 3 months! doi.org/10.1016/j.jtha… @JTHjournal @GaryRaskob @MarcCarrier1

Standardized PAUSE vs complex ASRA periprocedural #DOAC interruption for high #bleed risk procedures: results from PAUSE-2 pilot trial pubmed.ncbi.nlm.nih.gov/40086754/ @Vasculearn @AnticoagForum @PERTConsortium @ThrombosisCan @canvector @ThrombosisUK @EuropeanTHA @thrombosisday @escardio

Hereditary #antithrombin deficiency and venous thrombosis in pregnancy - results of a retrospective multicenter study jthjournal.org/article/S1538-…

Fantastic summary and recommendations on an underappreciated challenge by the @isth SSC Control of Anticoagulation @JTHjournal - FXaI interference with heparin anti-Xa measurement 🧪🩸 @CukerMd @GendronNico @LanaCastellucci jthjournal.org/article/S1538-…

The CAT-BLED study of 779 cancer patients shows that high GDF-15 levels are linked to major bleeding risks during systemic therapies. It highlights its potential as a key biomarker for bleeding risk prediction & prevention jacc.org/doi/abs/10.101… #JACCCardioOnc #VTE @Cihan_Ay_MD

🚨How to deal with interference on heparin anti-Xa activity caused by oral factor FXa inhibitors: Communication from the @isth SSC Subcommittee on Control of Anticoagulation @JTHjournal 🙏 Great team work with @CukerMd @LanaCastellucci @thachil jthjournal.org/article/S1538-…

The Repeat Study addressed a really important knowledge gap! The incidence of recurrent events following an ante- or postpartum VTE is 2.4% person-years. The cumulative risks are 6%, 13%, 17%, and 30% at 2, 5, 10, and 30 years respectively. jthjournal.org/article/S1538-…

In this meta-Analysis of 16 studies (2300+ patients), ✅ Peak & trough concentrations of apixaban and rivaroxaban established 📉 ✅ Age & kidney function impact drug levels—highlighting the need for personalized dosing ✅ Findings align with known pharmacokinetic studies 🔗jthjournal.org/article/S1538-…

The RENOVE trial found that while low-dose DOACs did not meet non-inferiority for preventing recurrent VTE, it showed a better risk-benefit ratio, with less clinically relevant bleeding. Dose reduction may be a good option for many patients! thelancet.com/journals/lance… @FCouturaud @INNOVTE1 @TheLancet

Individuals with a new cancer diagnosis and no stroke history have an increased risk of ischemic stroke which varies according to site and stage. Future research is needed to identify individuals at highest risk who may benefit from preventative treatment @DebSiegal 🔗jthjournal.org/article/S1538-…